SecBot SecBot
PRESS-RELEASE ·Filed May 21, 2026

ZNTL

ZENTALIS PHARMACEUTICALS
BULLISH
Impact 6/10
Horizondays Processed5mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Focus on ASCO presentation on June 1 for full data and any regulatory updates. The positive combination data supports azenosertib's broader potential, but the stock's history of large post-event reversals suggests caution on extended holding.

DirectionBullish
Confidencemedium
Horizondays

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.06
T+0 close · May 21, 2026 · via day close
Latest settled
−9.36%
T+60 · $3.68
Vs SPY
−12.55%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 22 $4.06entry
  2. T+1 · 6mo ago −2.46%α −3.05% · $3.96
  3. T+5 · 6mo ago −1.97%α −3.63% · $3.98
  4. T+20 · 5mo ago −8.87%α −7.45% · $3.70
  5. T+60 · 3mo ago −9.36%α −12.55% · $3.68

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Zentalis announced positive Phase 1b data for azenosertib plus paclitaxel in platinum-resistant ovarian cancer, with 39% ORR and 7.3-month median PFS in all-comers, and 50% ORR at the 250 mg intermittent dose. The data will be presented at ASCO 2026. The company also reported a Q1 2026 EPS miss of $-0.50 versus consensus $-0.46, though this is secondary for a pre-revenue biotech.

Key Financial Metrics

EPS
−$0.50
est −$0.46 · -8.7%
Revenue
$0.00
est $0.00 · 0.0%
Rating
miss

Key Facts

  • Phase 1b MUIR trial of azenosertib + paclitaxel showed 39% ORR and 7.3-month median PFS in all-comer PROC (n=46).
  • At the 250 mg 5:2 intermittent dose (n=12), ORR was 50% with median DOR of 9.2 months.
  • Clinical activity was comparable in Cyclin E1-positive and negative patients.
  • Manageable safety: Grade ≥3 neutropenia 30.4%, anemia 19.6%.
  • Data to be presented at ASCO 2026 on June 1.
  • Q1 2026 EPS of -$0.50 missed consensus of -$0.46 (-8.7% miss).

Financial Impact

Clinical data positive but early; EPS miss of $0.04 is immaterial for pre-revenue biotech; stock likely driven by ASCO data.

revenueeps

Risk Factors

  • Phase 1b data not yet confirmed in larger Phase 3 trials.
  • Competition from other WEE1 inhibitors and chemotherapy combos.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
60% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3299814

Track record

18 reports on ZNTL

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +51.42% at T+60 after the Aug 14, 2026 report. 6 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $1.62 Now $1.60 −1.23% settles Feb 12
  2. Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.80 Now $1.60 +11.11% settles Feb 8
  3. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $2.06 Now $1.60 −22.33% settles Jan 26
  4. Oct 18, 202629d ago Press Release Bullish 7/10 Entry $2.30 Now $1.60 −30.43% settles Jan 14
  5. Oct 1, 20266w ago Press Release Neutral 2/10 Entry $2.52 Now $1.60 −36.51% settles Dec 29
  6. Aug 14, 202613w ago 8-K Bearish 6/10 Entry $3.71 to $1.80 Now $1.60 +56.82% ▲ +51.42% +48.47% vs SPY
  7. Aug 13, 202613w ago Press Release Bearish 6/10 Entry $3.56 to $1.74 Now $1.60 +55.06% ▲ +51.12% +48.08% vs SPY
  8. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.75 to $4.03 Now $1.60 −57.33% ▲ +7.47% +4.20% vs SPY
  9. Jun 1, 202624w ago Press Release Neutral 2/10 Entry $3.95 to $3.89 Now $1.60 −59.49% ▼ −1.52% −2.64% vs SPY
  10. May 21, 202625w ago Press Release Bullish 6/10 Viewing Entry $4.06 to $3.68 Now $1.60 −60.59% ▼ −9.36% −12.55% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 8h 55m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 21, 2026